8-K ·Filed Apr 22, 2026

MEDP

Medpace Holdings, Inc.
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001668397-26-000017
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor the upcoming conference call for details on the leadership transition plan. The stock may react positively to the earnings beat but could face pressure due to executive instability. Watch for any changes to guidance in future updates.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
MEDP ▲ +34.19% at T+60d
NEUTRAL call ✓ call won +34.19% · α vs SPY +29.17% · entry $393.42 → $527.93
Entry anchored
Apr 22, 03:59 PM ET
via exchange tick
T+1d
+4.35%
call +4.35% · α +3.57%
$410.54
settled 5mo ago
T+5d
+5.13%
call +5.13% · α +3.65%
$413.59
settled 5mo ago
T+20d
+7.23%
call +7.23% · α +2.60%
$421.87
settled 5mo ago
T+60d
+34.19%
call +34.19% · α +29.17%
$527.93
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Medpace reported strong Q1 2026 earnings with revenue up 26.5% YoY and EPS of $4.28, beating consensus. However, President Jesse Geiger announced his resignation effective May 31, 2026, creating leadership uncertainty. The stock faces mixed signals from solid financials versus executive transition risk.

Key Financial Metrics

EPS
$4.28
est $3.74 · +14.4%
Revenue
$706.6M
est $697.6M · +1.3% · +26.5% YoY
Rating
beat
Guidance
$2.755B-$2.855B
maintained

Key Facts

  • Q1 2026 revenue: $706.6M, up 26.5% YoY
  • Q1 2026 EPS: $4.28, beating consensus of $3.74
  • President Jesse Geiger to resign May 31, 2026
  • CEO August Troendle to reassume President role temporarily
  • 2026 full-year guidance maintained at $2.755B-$2.855B revenue

Financial Impact

Revenue beat by $9.0M vs consensus, EPS beat by $0.54. Full-year guidance unchanged.

revenueepsnet incomecash flow

Risk Factors

  • Leadership transition could create execution risk
  • Potential client uncertainty during management change
  • Guidance assumes current leadership stability

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001668397-26-000017
Document: medp-20260421.htm0001668397-26-000017
Document: 0001668397-26-000017-index-headers.html0001668397-26-000017
Document: 0001668397-26-000017-index.html0001668397-26-000017
Document: 0001668397-26-000017.txt0001668397-26-000017
8-K Data (Synthetic)0001668397-26-000017
15 reports for MEDP
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +7.72%Dec 4, 2025
Filters
Rows
Reports for MEDP — sortable, filterable
TypeNow
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$593.99 $622.11▲ +4.73%▲ +4.92%$606.24 (+2.06%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 4/10
$600.65 $615.94▲ +2.55%▲ +2.29%$606.24 (+0.93%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$611.57 $620.59▲ +1.47%▲ +1.98%$606.24 (−0.87%)
Aug 25, 2026
5w ago
Insider Cluster
BEARISH ★ 5/10
$614.06 $617.15▼ −0.50%▲ +0.47%$606.24 (+1.27%)
Aug 24, 2026
5w ago
Insider Cluster
NEUTRAL ★ 4/10
$620.03 $630.19▲ +1.64%▲ +0.32%$606.24 (−2.22%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 3/10
$620.75 $624.20▲ +0.56%▲ +1.08%$606.24 (−2.34%)
Aug 19, 2026
6w ago
144
NEUTRAL ★ 3/10
$608.27 $615.18▲ +1.14%▲ +3.09%$606.24 (−0.33%)
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$578.50 $595.41▲ +2.92%▲ +4.91%$606.24 (+4.80%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$581.95 $587.52▲ +0.96%▲ +2.70%$606.24 (+4.17%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$596.98 $583.16▼ −2.31%▼ −0.42%$606.24 (+1.55%)
Showing 10 of 15

US Market Status

Market Open — Closes in 3h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access